Phase 4Not yet recruiting
Evaluation of the Efficacy and Acceptability of a Phytotherapy Combining Devil's Claw, Blackcurrant and Meadowsweet for the Management of Aromatase Inhibitor-induced Arthralgia in Patients Treated for Localized Breast Cancer in the Adjuvant Setting (ERABLE)
- Sponsor
- Hospices Civils de Lyon (Academic or other)
- Enrolment
- 105 planned
- Conditions
- Hormone Therapy-induced Arthralgia; Phytotherapy; Symptom Management; Adjuvant Treatment; Patient Acceptability; Joint Pain
- Interventions
- Phytotherapy Dietary Supplement (Harpagophytum, Meadowsweet, and Blackcurrant); Patient Experience Questionnaire
- Ages
- adults, older adults
- Registry
- NCT07859319
Full record on ClinicalTrials.gov
From the registry
Adjuvant hormonotherapy is a cornerstone of treatment for localized hormone receptor-positive (HR+) breast cancer, accounting for approximately 80% of patients. The main classes used are selective estrogen receptor modulators (SERMs, including tamoxifen) and aromatase inhibitors (anastrozole, letrozole, exemestane), with or without LH-RH agonists (leuprorelin, goserelin), administered daily for 5 to 8 years. However, these treatments are frequently associated with adverse events, predominantly musculoskeletal disorders such as arthralgia, which can significantly impair quality of life. These symptoms cause functional impact and promote premature discontinuation of treatment, thereby compromising therapeutic adherence and increasing the risk of tumor relapse. Current management strategies for these arthralgias, whether pharmacological or non-pharmacological, show limited efficacy or insufficient levels of evidence, with the exception of certain approaches like acupuncture. In the absence of satisfactory solutions, many patients turn to alternative medicines, notably phytotherapy.…
Primary outcomes
- Change in joint pain score from baseline to day 21
History
Primary completion expected
Expected to start
Registered